Header Logo

Connection

JOSEPH JANKOVIC to Adult

Back to Details
This is a "connection" page, showing publications JOSEPH JANKOVIC has written about Adult.
JOSEPH JANKOVIC
Connection Strength
2.966
Adult
  1. Functional Head Tremor: Contrasting Features with Other Tremor Etiologies. Mov Disord Clin Pract. 2025 Dec; 12(12):2289-2295.
    View in: PubMed
    Score: 0.054
  2. Axial tics in Tourette syndrome and chronic tic disorders. J Neurol. 2024 Nov; 271(11):7232-7238.
    View in: PubMed
    Score: 0.051
  3. Treatment response to onabotulinumtoxinA in cervical dystonia patients with anterocollis and retrocollis. Toxicon. 2024 Sep; 248:108035.
    View in: PubMed
    Score: 0.051
  4. Functional Neurological Disorders Among Patients With Tremor. J Neuropsychiatry Clin Neurosci. 2025; 37(1):61-66.
    View in: PubMed
    Score: 0.051
  5. Medication refractory restless legs syndrome: Real-world experience. J Neurol Sci. 2024 Aug 15; 463:123121.
    View in: PubMed
    Score: 0.051
  6. Leg stereotypy syndrome: phenomenological and quantitative analysis. J Neurol. 2024 Aug; 271(8):5519-5524.
    View in: PubMed
    Score: 0.050
  7. Treatment of cervical dystonia with Botox (onabotulinumtoxinA): Development, insights, and impact. Medicine (Baltimore). 2023 Jul 01; 102(S1):e32403.
    View in: PubMed
    Score: 0.047
  8. Duration and onset of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-na?ve subjects. Curr Med Res Opin. 2021 10; 37(10):1761-1768.
    View in: PubMed
    Score: 0.041
  9. Psychogenic (Functional) Movement Disorders. Continuum (Minneap Minn). 2019 Aug; 25(4):1121-1140.
    View in: PubMed
    Score: 0.036
  10. Young-onset Parkinson's disease: Its unique features and their impact on quality of life. Parkinsonism Relat Disord. 2019 08; 65:39-48.
    View in: PubMed
    Score: 0.036
  11. Clinical phenotype in carriers of intermediate alleles in the huntingtin gene. J Neurol Sci. 2019 Jul 15; 402:57-61.
    View in: PubMed
    Score: 0.035
  12. Real-World Experience With VMAT2 Inhibitors. Clin Neuropharmacol. 2019 Mar/Apr; 42(2):37-41.
    View in: PubMed
    Score: 0.035
  13. Botulinum Toxin for the Treatment of Hand Tremor. Toxins (Basel). 2018 07 19; 10(7).
    View in: PubMed
    Score: 0.033
  14. Cervical dystonia and substance abuse. J Neurol. 2018 Apr; 265(4):970-975.
    View in: PubMed
    Score: 0.033
  15. Leg stereotypy syndrome: phenomenology and prevalence. J Neurol Neurosurg Psychiatry. 2018 07; 89(7):692-695.
    View in: PubMed
    Score: 0.032
  16. Functional (psychogenic) stereotypies. J Neurol. 2017 Jul; 264(7):1482-1487.
    View in: PubMed
    Score: 0.031
  17. Apraclonidine in the treatment of ptosis. J Neurol Sci. 2017 May 15; 376:129-132.
    View in: PubMed
    Score: 0.030
  18. Examiner manoeuvres 'sensory tricks' in functional (psychogenic) movement disorders. J Neurol Neurosurg Psychiatry. 2017 05; 88(5):453-455.
    View in: PubMed
    Score: 0.030
  19. Distinguishing features of psychogenic (functional) versus organic hemifacial spasm. J Neurol. 2017 Feb; 264(2):359-363.
    View in: PubMed
    Score: 0.030
  20. Psychogenic Ophthalmologic Movement Disorders. J Neuropsychiatry Clin Neurosci. 2016; 28(3):195-8.
    View in: PubMed
    Score: 0.028
  21. Speech and voice disorders in patients with psychogenic movement disorders. J Neurol. 2015 Nov; 262(11):2420-4.
    View in: PubMed
    Score: 0.027
  22. Dopamine transporter imaging in essential tremor with and without parkinsonian features. J Neural Transm (Vienna). 2015 Nov; 122(11):1515-21.
    View in: PubMed
    Score: 0.027
  23. Dopa-responsive dystonia--clinical and genetic heterogeneity. Nat Rev Neurol. 2015 Jul; 11(7):414-24.
    View in: PubMed
    Score: 0.027
  24. Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE). J Neurol Sci. 2015 Feb 15; 349(1-2):84-93.
    View in: PubMed
    Score: 0.026
  25. Stiff-person syndrome: insights into a complex autoimmune disorder. J Neurol Neurosurg Psychiatry. 2015 Aug; 86(8):840-8.
    View in: PubMed
    Score: 0.026
  26. Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease. Parkinsonism Relat Disord. 2014 Dec; 20(12):1345-51.
    View in: PubMed
    Score: 0.026
  27. The clinical features of psychogenic movement disorders resembling tics. J Neurol Neurosurg Psychiatry. 2014 May; 85(5):573-5.
    View in: PubMed
    Score: 0.024
  28. Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. Mov Disord. 2014 Jan; 29(1):126-30.
    View in: PubMed
    Score: 0.024
  29. Deep brain stimulation of the subthalamic nucleus for peripherally induced parkinsonism. Neuromodulation. 2014 Jan; 17(1):104-6.
    View in: PubMed
    Score: 0.023
  30. Zolpidem improves tardive dyskinesia and akathisia. Mov Disord. 2013 Oct; 28(12):1748-9.
    View in: PubMed
    Score: 0.023
  31. Analysis of CYP2D6 genotype and response to tetrabenazine. Mov Disord. 2013 Feb; 28(2):210-5.
    View in: PubMed
    Score: 0.023
  32. Respiratory disorders associated with dystonia. Mov Disord. 2012 Dec; 27(14):1816-9.
    View in: PubMed
    Score: 0.023
  33. Amplitude fluctuations in essential tremor. Parkinsonism Relat Disord. 2012 Aug; 18(7):859-63.
    View in: PubMed
    Score: 0.022
  34. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study. Parkinsonism Relat Disord. 2012 Jun; 18(5):488-93.
    View in: PubMed
    Score: 0.021
  35. Convergence spasm in conversion disorders: prevalence in psychogenic and other movement disorders compared with controls. J Neurol Neurosurg Psychiatry. 2012 Feb; 83(2):202-4.
    View in: PubMed
    Score: 0.021
  36. Parkinsonism and dystonia associated with adalimumab. Mov Disord. 2011 Jul; 26(8):1556-8.
    View in: PubMed
    Score: 0.020
  37. Transcutaneous electrical stimulation (TENS) for psychogenic movement disorders. J Neuropsychiatry Clin Neurosci. 2011; 23(2):141-8.
    View in: PubMed
    Score: 0.020
  38. Asian over-representation among patients with hemifacial spasm compared to patients with cranial-cervical dystonia. J Neurol Sci. 2010 Nov 15; 298(1-2):61-3.
    View in: PubMed
    Score: 0.020
  39. Psychogenic chorea associated with family history of Huntington disease. Mov Disord. 2010 Mar 15; 25(4):503-4.
    View in: PubMed
    Score: 0.019
  40. Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm. Eur J Neurol. 2009 Dec; 16 Suppl 2:14-8.
    View in: PubMed
    Score: 0.018
  41. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry. 2010 Jan; 81(1):70-3.
    View in: PubMed
    Score: 0.018
  42. Spinocerebellar ataxia 8: variable phenotype and unique pathogenesis. Parkinsonism Relat Disord. 2009 Nov; 15(9):621-6.
    View in: PubMed
    Score: 0.018
  43. Motor overflow and mirror dystonia. Parkinsonism Relat Disord. 2009 Dec; 15(10):758-61.
    View in: PubMed
    Score: 0.018
  44. Hemidystonia-hemiatrophy syndrome. Mov Disord. 2009 Mar 15; 24(4):583-9.
    View in: PubMed
    Score: 0.018
  45. Epidemiology and management of essential tremor in children. Paediatr Drugs. 2009; 11(5):293-307.
    View in: PubMed
    Score: 0.017
  46. Genetic study of an American family with DYT3 dystonia (lubag). Neurosci Lett. 2008 Dec 26; 448(2):180-3.
    View in: PubMed
    Score: 0.017
  47. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol. 2008 May-Jun; 31(3):127-33.
    View in: PubMed
    Score: 0.016
  48. Mutation analysis of the parkin and PINK1 genes in American Caucasian early-onset Parkinson disease families. Neurosci Lett. 2008 Jan 03; 430(1):18-22.
    View in: PubMed
    Score: 0.016
  49. Hemiparkinsonism-hemiatrophy syndrome. Neurology. 2007 Oct 16; 69(16):1585-94.
    View in: PubMed
    Score: 0.016
  50. Focal hand dystonia, mirror dystonia and motor overflow. J Neurol Sci. 2008 Mar 15; 266(1-2):31-3.
    View in: PubMed
    Score: 0.016
  51. Malignant Tourette syndrome. Mov Disord. 2007 Sep 15; 22(12):1743-50.
    View in: PubMed
    Score: 0.016
  52. Distinguishing psychogenic and essential tremor. J Neurol Sci. 2007 Dec 15; 263(1-2):94-9.
    View in: PubMed
    Score: 0.016
  53. Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders. J Neurosurg. 2007 Apr; 106(4):621-5.
    View in: PubMed
    Score: 0.015
  54. Genetics of essential tremor. Brain. 2007 Jun; 130(Pt 6):1456-64.
    View in: PubMed
    Score: 0.015
  55. A family with Parkinson disease, essential tremor, bell palsy, and parkin mutations. Arch Neurol. 2007 Mar; 64(3):421-4.
    View in: PubMed
    Score: 0.015
  56. Adult onset tics after peripheral injury. Parkinsonism Relat Disord. 2008; 14(1):75-6.
    View in: PubMed
    Score: 0.015
  57. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007 Jan 15; 22(2):193-7.
    View in: PubMed
    Score: 0.015
  58. Short-term effects of tetrabenazine on chorea associated with Huntington's disease. Mov Disord. 2007 Jan; 22(1):10-3.
    View in: PubMed
    Score: 0.015
  59. Comparing knowledge and attitudes towards genetic testing in Parkinson's disease in an American and Asian population. J Neurol Sci. 2007 Jan 31; 252(2):113-20.
    View in: PubMed
    Score: 0.015
  60. Examination of the SLITRK1 gene in Caucasian patients with Tourette syndrome. Acta Neurol Scand. 2006 Dec; 114(6):400-2.
    View in: PubMed
    Score: 0.015
  61. Genetic analysis of LRRK2 mutations in patients with Parkinson disease. J Neurol Sci. 2006 Dec 21; 251(1-2):102-6.
    View in: PubMed
    Score: 0.015
  62. Runner's dystonia. J Neurol Sci. 2006 Dec 21; 251(1-2):73-6.
    View in: PubMed
    Score: 0.015
  63. Botulinum toxin injection for congenital muscular torticollis presenting in children and adults. Neurology. 2006 Sep 26; 67(6):1083-5.
    View in: PubMed
    Score: 0.015
  64. Botulinum toxin treatment of facial myoclonus in suspected Rasmussen encephalitis. Mov Disord. 2006 Sep; 21(9):1500-2.
    View in: PubMed
    Score: 0.015
  65. Is history of depression a contraindication to treatment with tetrabenazine? Clin Neuropharmacol. 2006 Sep-Oct; 29(5):259-64.
    View in: PubMed
    Score: 0.015
  66. The LRRK2 I2012T, G2019S and I2020T mutations are not common in patients with essential tremor. Neurosci Lett. 2006 Oct 23; 407(2):97-100.
    View in: PubMed
    Score: 0.015
  67. Subthalamic deep brain stimulation in patients with a previous pallidotomy. Mov Disord. 2006 Aug; 21(8):1252-4.
    View in: PubMed
    Score: 0.015
  68. Effect of vagal nerve stimulation in a case of Tourette's syndrome and complex partial epilepsy. Mov Disord. 2006 Aug; 21(8):1273-5.
    View in: PubMed
    Score: 0.015
  69. Psychogenic tremor: long-term outcome. CNS Spectr. 2006 Jul; 11(7):501-8.
    View in: PubMed
    Score: 0.015
  70. A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc Natl Acad Sci U S A. 2006 Jul 11; 103(28):10753-8.
    View in: PubMed
    Score: 0.015
  71. Long-term prognosis of patients with psychogenic movement disorders. Parkinsonism Relat Disord. 2006 Sep; 12(6):382-7.
    View in: PubMed
    Score: 0.014
  72. Globus pallidus deep brain stimulation in dystonia. Mov Disord. 2006 May; 21(5):692-5.
    View in: PubMed
    Score: 0.014
  73. Gene dosage analysis of alpha-synuclein (SNCA) in patients with Parkinson's disease. Mov Disord. 2006 May; 21(5):728-9.
    View in: PubMed
    Score: 0.014
  74. Genetic analysis of the GABRA1 gene in patients with essential tremor. Neurosci Lett. 2006 Jun 19; 401(1-2):16-9.
    View in: PubMed
    Score: 0.014
  75. Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations. Arch Neurol. 2006 Feb; 63(2):273-7.
    View in: PubMed
    Score: 0.014
  76. Tourette's syndrome and the law. J Neuropsychiatry Clin Neurosci. 2006; 18(1):86-95.
    View in: PubMed
    Score: 0.014
  77. Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial. Neurology. 2005 Sep 13; 65(5):765-7.
    View in: PubMed
    Score: 0.014
  78. G309D and W437OPA PINK1 mutations in Caucasian Parkinson's disease patients. Acta Neurol Scand. 2005 Jun; 111(6):351-2.
    View in: PubMed
    Score: 0.013
  79. Secondary tics and tourettism. Braz J Psychiatry. 2005 Mar; 27(1):11-7.
    View in: PubMed
    Score: 0.013
  80. Genetic analysis of parkin co-regulated gene (PACRG) in patients with early-onset parkinsonism. Neurosci Lett. 2005 Jul 15; 382(3):297-9.
    View in: PubMed
    Score: 0.013
  81. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord. 2005; 20 Suppl 11:S11-6.
    View in: PubMed
    Score: 0.013
  82. Factor analysis and clustering of motor and psychiatric dimensions in idiopathic blepharospasm. Parkinsonism Relat Disord. 2025 Feb; 131:107241.
    View in: PubMed
    Score: 0.013
  83. Premutation alleles associated with Parkinson disease and essential tremor. JAMA. 2004 Oct 13; 292(14):1685-6.
    View in: PubMed
    Score: 0.013
  84. Glabellar and palmomental reflexes in Parkinsonian disorders. Neurology. 2004 Sep 28; 63(6):1096-8.
    View in: PubMed
    Score: 0.013
  85. Minocycline in Huntington's disease: a pilot study. Mov Disord. 2004 Jun; 19(6):692-5.
    View in: PubMed
    Score: 0.013
  86. Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled Trial. Neurology. 2024 02 27; 102(4):e208091.
    View in: PubMed
    Score: 0.012
  87. Basal ganglia neuronal discharge in primary and secondary dystonia. Adv Neurol. 2004; 94:29-36.
    View in: PubMed
    Score: 0.012
  88. Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden-Spatz syndrome) and pantothenate kinase-associated neurodegeneration. Mov Disord. 2004 Jan; 19(1):36-42.
    View in: PubMed
    Score: 0.012
  89. Premonitory sensory phenomenon in Tourette's syndrome. Mov Disord. 2003 Dec; 18(12):1530-3.
    View in: PubMed
    Score: 0.012
  90. Migraine headache in patients with Tourette syndrome. Arch Neurol. 2003 Nov; 60(11):1595-8.
    View in: PubMed
    Score: 0.012
  91. MDMA and Parkinsonism. N Engl J Med. 2003 Jul 03; 349(1):96-7.
    View in: PubMed
    Score: 0.012
  92. Basal ganglia neuronal discharge in primary and secondary dystonia in patients undergoing pallidotomy. Neurosurgery. 2003 Jun; 52(6):1358-70; discussion 1370-3.
    View in: PubMed
    Score: 0.012
  93. Soleus H-reflex measures in patients with focal and generalized dystonia. Clin Neurophysiol. 2003 Feb; 114(2):288-94.
    View in: PubMed
    Score: 0.011
  94. Movement disorders in Friedreich's ataxia. J Neurol Sci. 2003 Jan 15; 206(1):59-64.
    View in: PubMed
    Score: 0.011
  95. Tetrabenazine treatment for Huntington's disease-associated chorea. Clin Neuropharmacol. 2002 Nov-Dec; 25(6):300-2.
    View in: PubMed
    Score: 0.011
  96. Secondary paroxysmal dyskinesias. Mov Disord. 2002 Jul; 17(4):726-34.
    View in: PubMed
    Score: 0.011
  97. Tourettism and dystonia after subcortical stroke. Mov Disord. 2002 Jul; 17(4):821-5.
    View in: PubMed
    Score: 0.011
  98. H-reflex recovery curves differentiate essential tremor, Parkinson's disease, and the combination of essential tremor and Parkinson's disease. J Clin Neurophysiol. 2002 Jun; 19(3):245-51.
    View in: PubMed
    Score: 0.011
  99. Association of Essential Tremor With Novel Risk Loci: A Genome-Wide Association Study and Meta-analysis. JAMA Neurol. 2022 02 01; 79(2):185-193.
    View in: PubMed
    Score: 0.011
  100. Methods of H-reflex evaluation in the early stages of Parkinson's disease. J Clin Neurophysiol. 2002 Jan; 19(1):67-72.
    View in: PubMed
    Score: 0.011
  101. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology. 2001 Oct 23; 57(8):1392-6.
    View in: PubMed
    Score: 0.010
  102. Functional decline in Parkinson disease. Arch Neurol. 2001 Oct; 58(10):1611-5.
    View in: PubMed
    Score: 0.010
  103. Predictive modeling of spread in adult-onset isolated dystonia: Key properties and effect of tremor inclusion. Eur J Neurol. 2021 12; 28(12):3999-4009.
    View in: PubMed
    Score: 0.010
  104. Concepts and methods in chronic thalamic stimulation for treatment of tremor: technique and application. Neurosurgery. 2001 Mar; 48(3):535-41; discussion 541-3.
    View in: PubMed
    Score: 0.010
  105. Dystonia in corticobasal degeneration. Mov Disord. 2001 Mar; 16(2):252-7.
    View in: PubMed
    Score: 0.010
  106. Effects of pallidotomy on gait and balance. Adv Neurol. 2001; 87:271-81.
    View in: PubMed
    Score: 0.010
  107. Psychogenic hemifacial spasm. J Neuropsychiatry Clin Neurosci. 2001; 13(3):380-4.
    View in: PubMed
    Score: 0.010
  108. Dystonia and Tremor: A Cross-Sectional Study of the Dystonia Coalition Cohort. Neurology. 2021 01 26; 96(4):e563-e574.
    View in: PubMed
    Score: 0.010
  109. Botulinum toxin in the treatment of tics. Arch Neurol. 2000 Aug; 57(8):1190-3.
    View in: PubMed
    Score: 0.010
  110. Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial. Mov Disord. 2000 Jul; 15(4):678-82.
    View in: PubMed
    Score: 0.010
  111. Tardive and idiopathic oromandibular dystonia: a clinical comparison. J Neurol Neurosurg Psychiatry. 2000 Feb; 68(2):186-90.
    View in: PubMed
    Score: 0.009
  112. Treating severe bruxism with botulinum toxin. J Am Dent Assoc. 2000 Feb; 131(2):211-6.
    View in: PubMed
    Score: 0.009
  113. Essential tremor: clinical characteristics. Neurology. 2000; 54(11 Suppl 4):S21-5.
    View in: PubMed
    Score: 0.009
  114. Functional gait disorders, clinical phenomenology, and classification. Neurol Sci. 2020 Apr; 41(4):911-915.
    View in: PubMed
    Score: 0.009
  115. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology. 1999 Dec 10; 53(9):2102-7.
    View in: PubMed
    Score: 0.009
  116. Bilineal transmission in Tourette syndrome. Neurology. 1999 Sep 11; 53(4):813-8.
    View in: PubMed
    Score: 0.009
  117. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry. 1999 Aug; 156(8):1279-81.
    View in: PubMed
    Score: 0.009
  118. Levodopa-induced dyskinesias treated by pallidotomy. J Neurol Sci. 1999 Aug 01; 167(1):62-7.
    View in: PubMed
    Score: 0.009
  119. Bruxism and cranial-cervical dystonia: is there a relationship? Cranio. 1999 Jul; 17(3):196-201.
    View in: PubMed
    Score: 0.009
  120. Autosomal dominant mitochondrial membrane protein-associated neurodegeneration (MPAN). Mol Genet Genomic Med. 2019 07; 7(7):e00736.
    View in: PubMed
    Score: 0.009
  121. Parkinson's disease age at onset genome-wide association study: Defining heritability, genetic loci, and a-synuclein mechanisms. Mov Disord. 2019 06; 34(6):866-875.
    View in: PubMed
    Score: 0.009
  122. Movement and reaction times and fine coordination tasks following pallidotomy. Mov Disord. 1999 Jan; 14(1):57-62.
    View in: PubMed
    Score: 0.009
  123. Efficacy and tolerability of a novel sublingual apomorphine preparation in patients with fluctuating Parkinson's disease. Clin Neuropharmacol. 1999 Jan-Feb; 22(1):1-4.
    View in: PubMed
    Score: 0.009
  124. Attitudes toward neurosurgical procedures for Parkinson's disease and obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci. 1999; 11(2):259-67.
    View in: PubMed
    Score: 0.009
  125. Hemifacial spasm: clinical findings and treatment. Muscle Nerve. 1998 Dec; 21(12):1740-7.
    View in: PubMed
    Score: 0.009
  126. Peripherally induced oromandibular dystonia. J Neurol Neurosurg Psychiatry. 1998 Nov; 65(5):722-8.
    View in: PubMed
    Score: 0.009
  127. Predictors of alcohol responsiveness in dystonia. Neurology. 2018 11 20; 91(21):e2020-e2026.
    View in: PubMed
    Score: 0.009
  128. Mouse bioassay versus Western blot assay for botulinum toxin antibodies: correlation with clinical response. Neurology. 1998 Jun; 50(6):1624-9.
    View in: PubMed
    Score: 0.008
  129. Post-traumatic movement disorders: effect of the legal system on outcome. J Forensic Sci. 1998 Mar; 43(2):334-9.
    View in: PubMed
    Score: 0.008
  130. Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease. Brain. 2017 12 01; 140(12):3191-3203.
    View in: PubMed
    Score: 0.008
  131. Tics secondary to craniocerebral trauma. Mov Disord. 1997 Sep; 12(5):776-82.
    View in: PubMed
    Score: 0.008
  132. ADCY5-related movement disorders: Frequency, disease course and phenotypic variability in a cohort of paediatric patients. Parkinsonism Relat Disord. 2017 Aug; 41:37-43.
    View in: PubMed
    Score: 0.008
  133. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology. 1997 Feb; 48(2):358-62.
    View in: PubMed
    Score: 0.008
  134. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. JAMA Neurol. 2017 Feb 01; 74(2):216-224.
    View in: PubMed
    Score: 0.008
  135. Thalamic surgery for movement disorders. Adv Neurol. 1997; 74:221-33.
    View in: PubMed
    Score: 0.008
  136. [Medial posteroventral pallidotomy for the treatment of Parkinson's disease]. Zentralbl Neurochir. 1997; 58(4):153-62.
    View in: PubMed
    Score: 0.008
  137. A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology. 2017 Jan 10; 88(2):152-159.
    View in: PubMed
    Score: 0.007
  138. Restless legs syndrome: clinicoetiologic correlates. Neurology. 1996 Dec; 47(6):1435-41.
    View in: PubMed
    Score: 0.007
  139. Submolecular recognition regions of the HN domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients. J Neuroimmunol. 2016 11 15; 300:36-46.
    View in: PubMed
    Score: 0.007
  140. Severe motor tics causing cervical myelopathy in Tourette's syndrome. Mov Disord. 1996 Sep; 11(5):563-6.
    View in: PubMed
    Score: 0.007
  141. Cervical dystonia as the initial presentation of Huntington's disease. Mov Disord. 1996 Jul; 11(4):457-9.
    View in: PubMed
    Score: 0.007
  142. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. JAMA Neurol. 2016 Jan; 73(1):102-10.
    View in: PubMed
    Score: 0.007
  143. Whole-Exome Sequencing in Familial Parkinson Disease. JAMA Neurol. 2016 Jan; 73(1):68-75.
    View in: PubMed
    Score: 0.007
  144. Delayed-onset progressive movement disorders after static brain lesions. Neurology. 1996 Jan; 46(1):68-74.
    View in: PubMed
    Score: 0.007
  145. Submolecular recognition of the C-terminal domain of the heavy chain of botulinum neurotoxin type A by T cells from toxin-treated cervical dystonia patients. Immunobiology. 2016 Apr; 221(4):568-76.
    View in: PubMed
    Score: 0.007
  146. Movement Disorders From the Use of Metoclopramide and Other Antiemetics in the Treatment of Migraine. Headache. 2016 Jan; 56(1):153-61.
    View in: PubMed
    Score: 0.007
  147. Paroxysmal dyskinesias: clinical features and classification. Ann Neurol. 1995 Oct; 38(4):571-9.
    View in: PubMed
    Score: 0.007
  148. Outcome after stereotactic thalamotomy for parkinsonian, essential, and other types of tremor. Neurosurgery. 1995 Oct; 37(4):680-6; discussion 686-7.
    View in: PubMed
    Score: 0.007
  149. Response and immunoresistance to botulinum toxin injections. Neurology. 1995 Sep; 45(9):1743-6.
    View in: PubMed
    Score: 0.007
  150. Emotional and functional impact of DNA testing on patients with symptoms of Huntington's disease. J Med Genet. 1995 Jul; 32(7):516-8.
    View in: PubMed
    Score: 0.007
  151. Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol. 2015 Jul; 14(7):710-9.
    View in: PubMed
    Score: 0.007
  152. Tremor and longevity in relatives of patients with Parkinson's disease, essential tremor, and control subjects. Neurology. 1995 Apr; 45(4):645-8.
    View in: PubMed
    Score: 0.007
  153. Peripherally induced tremor and parkinsonism. Arch Neurol. 1995 Mar; 52(3):263-70.
    View in: PubMed
    Score: 0.007
  154. Tourettism associated with Huntington's disease. Mov Disord. 1995 Jan; 10(1):103-5.
    View in: PubMed
    Score: 0.007
  155. Post-traumatic movement disorders: central and peripheral mechanisms. Neurology. 1994 Nov; 44(11):2006-14.
    View in: PubMed
    Score: 0.006
  156. Cross-disorder genome-wide analyses suggest a complex genetic relationship between Tourette's syndrome and OCD. Am J Psychiatry. 2015 Jan; 172(1):82-93.
    View in: PubMed
    Score: 0.006
  157. Neurohistopathological findings at the electrode-tissue interface in long-term deep brain stimulation: systematic literature review, case report, and assessment of stimulation threshold safety. Neuromodulation. 2014 Jul; 17(5):405-18; discussion 418.
    View in: PubMed
    Score: 0.006
  158. CAG repeat size and clinical presentation in Huntington's disease. Neurology. 1994 Jun; 44(6):1137-43.
    View in: PubMed
    Score: 0.006
  159. Peptidoglycan recognition protein genes and risk of Parkinson's disease. Mov Disord. 2014 Aug; 29(9):1171-80.
    View in: PubMed
    Score: 0.006
  160. Alleviating manoeuvres (sensory tricks) in cervical dystonia. J Neurol Neurosurg Psychiatry. 2014 Aug; 85(8):882-4.
    View in: PubMed
    Score: 0.006
  161. Botulinum toxin in the treatment of dystonic tics. Mov Disord. 1994 May; 9(3):347-9.
    View in: PubMed
    Score: 0.006
  162. Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy). J Neurol. 2014 Jul; 261(7):1309-19.
    View in: PubMed
    Score: 0.006
  163. Bilateral pallidal deep brain stimulation for X-linked dystonia-parkinsonism. World Neurosurg. 2014 Jul-Aug; 82(1-2):241.e1-4.
    View in: PubMed
    Score: 0.006
  164. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med. 1993 Jul; 95(1):38-48.
    View in: PubMed
    Score: 0.006
  165. Tardive stereotypy and other movement disorders in tardive dyskinesias. Neurology. 1993 May; 43(5):937-41.
    View in: PubMed
    Score: 0.006
  166. Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology. 2013 May 28; 80(22):2022-7.
    View in: PubMed
    Score: 0.006
  167. Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia. Neurology. 1993 Apr; 43(4):834-6.
    View in: PubMed
    Score: 0.006
  168. Cocaine-related movement disorders. Mov Disord. 1993 Apr; 8(2):175-8.
    View in: PubMed
    Score: 0.006
  169. Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(?)) injections in blepharospasm. J Neural Transm (Vienna). 2013 Sep; 120(9):1345-53.
    View in: PubMed
    Score: 0.006
  170. Psychogenic myoclonus. Neurology. 1993 Feb; 43(2):349-52.
    View in: PubMed
    Score: 0.006
  171. Reliability of a new scale for essential tremor. Mov Disord. 2012 Oct; 27(12):1567-9.
    View in: PubMed
    Score: 0.006
  172. Mutation screening of the HTR2B gene in patients with Tourette syndrome. Neurosci Lett. 2012 Sep 27; 526(2):150-3.
    View in: PubMed
    Score: 0.006
  173. Deep brain stimulation hardware complications in patients with movement disorders: risk factors and clinical correlations. Stereotact Funct Neurosurg. 2012; 90(5):300-6.
    View in: PubMed
    Score: 0.006
  174. Acoustic reflex abnormalities in cranial-cervical dystonia. Neurology. 1992 Mar; 42(3 Pt 1):594-7.
    View in: PubMed
    Score: 0.005
  175. Head injury, a-synuclein Rep1, and Parkinson's disease. Ann Neurol. 2012 Jan; 71(1):40-8.
    View in: PubMed
    Score: 0.005
  176. Clinical correlates of response to botulinum toxin injections. Arch Neurol. 1991 Dec; 48(12):1253-6.
    View in: PubMed
    Score: 0.005
  177. Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B. J Neuroimmunol. 2011 Dec 15; 240-241:121-8.
    View in: PubMed
    Score: 0.005
  178. Reflexive and volitional saccades: biomarkers of Huntington disease severity and progression. J Neurol Sci. 2012 Feb 15; 313(1-2):35-41.
    View in: PubMed
    Score: 0.005
  179. The coexistence of tics and dystonia. Arch Neurol. 1991 Aug; 48(8):862-5.
    View in: PubMed
    Score: 0.005
  180. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN?, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011 Sep 15; 308(1-2):103-9.
    View in: PubMed
    Score: 0.005
  181. Human T-cell responses to botulinum neurotoxin: proliferative responses in vitro of lymphocytes from botulinum neurotoxin A-treated movement disorder patients. J Neuroimmunol. 2011 Aug 15; 237(1-2):66-72.
    View in: PubMed
    Score: 0.005
  182. Cervical dystonia: clinical findings and associated movement disorders. Neurology. 1991 Jul; 41(7):1088-91.
    View in: PubMed
    Score: 0.005
  183. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 2011 May; 10(5):415-23.
    View in: PubMed
    Score: 0.005
  184. Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. Am J Pathol. 2011 Apr; 178(4):1509-16.
    View in: PubMed
    Score: 0.005
  185. Essential tremor: clinical correlates in 350 patients. Neurology. 1991 Feb; 41(2 ( Pt 1)):234-8.
    View in: PubMed
    Score: 0.005
  186. Dystonic tics in patients with Tourette's syndrome. Mov Disord. 1991; 6(3):248-52.
    View in: PubMed
    Score: 0.005
  187. CSF A?(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord. 2010 Nov 15; 25(15):2682-5.
    View in: PubMed
    Score: 0.005
  188. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010 Dec; 9(12):1164-1172.
    View in: PubMed
    Score: 0.005
  189. LINGO1 rs9652490 variant in Parkinson disease patients. Neurosci Lett. 2011 Jan 07; 487(2):174-6.
    View in: PubMed
    Score: 0.005
  190. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology. 1990 Oct; 40(10):1529-34.
    View in: PubMed
    Score: 0.005
  191. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord. 2011 Jan; 26(1):147-52.
    View in: PubMed
    Score: 0.005
  192. Botulinum toxin treatment of cranial-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry. 1990 Aug; 53(8):633-9.
    View in: PubMed
    Score: 0.005
  193. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett. 2010 Aug 09; 480(1):78-82.
    View in: PubMed
    Score: 0.005
  194. Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study. Hum Mutat. 2010 May; 31(5):561-8.
    View in: PubMed
    Score: 0.005
  195. Neurologic approach to drug-induced movement disorders: a study of 125 patients. South Med J. 1990 May; 83(5):525-32.
    View in: PubMed
    Score: 0.005
  196. LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease. Neurogenetics. 2010 Oct; 11(4):401-8.
    View in: PubMed
    Score: 0.005
  197. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010 Jun; 16(5):316-23.
    View in: PubMed
    Score: 0.005
  198. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain. 2010 Mar; 133(Pt 3):713-26.
    View in: PubMed
    Score: 0.005
  199. Botulinum toxin injections for cervical dystonia. Neurology. 1990 Feb; 40(2):277-80.
    View in: PubMed
    Score: 0.005
  200. Sulpiride-induced tardive dystonia. Mov Disord. 1990; 5(1):83-4.
    View in: PubMed
    Score: 0.005
  201. Metoclopramide-induced movement disorders. Clinical findings with a review of the literature. Arch Intern Med. 1989 Nov; 149(11):2486-92.
    View in: PubMed
    Score: 0.005
  202. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009 Sep 24; 361(13):1268-78.
    View in: PubMed
    Score: 0.005
  203. Occupation and risk of parkinsonism: a multicenter case-control study. Arch Neurol. 2009 Sep; 66(9):1106-13.
    View in: PubMed
    Score: 0.005
  204. Hemiballism-hemichorea. Clinical and pharmacologic findings in 21 patients. Arch Neurol. 1989 Aug; 46(8):862-7.
    View in: PubMed
    Score: 0.004
  205. Dystonia in musicians. Semin Neurol. 1989 Jun; 9(2):131-5.
    View in: PubMed
    Score: 0.004
  206. Lrrk2 R1441G-related Parkinson's disease: evidence of a common founding event in the seventh century in Northern Spain. Neurogenetics. 2009 Oct; 10(4):347-53.
    View in: PubMed
    Score: 0.004
  207. Dystonia and tremor induced by peripheral trauma: predisposing factors. J Neurol Neurosurg Psychiatry. 1988 Dec; 51(12):1512-9.
    View in: PubMed
    Score: 0.004
  208. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord. 2008 Nov 15; 23(15):2194-201.
    View in: PubMed
    Score: 0.004
  209. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15; 23(15):2129-70.
    View in: PubMed
    Score: 0.004
  210. Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A. Neurology. 2008 Sep 23; 71(13):1040; author reply 1040-1.
    View in: PubMed
    Score: 0.004
  211. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008 Jul 30; 23(10):1353-60.
    View in: PubMed
    Score: 0.004
  212. Five-year follow-up of unilateral posteroventral pallidotomy in Parkinson's disease. Surg Neurol. 2009 May; 71(5):551-8.
    View in: PubMed
    Score: 0.004
  213. Focal task-specific tremor and dystonia: categorization of occupational movement disorders. Neurology. 1988 Apr; 38(4):522-7.
    View in: PubMed
    Score: 0.004
  214. Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform. J Proteome Res. 2008 Feb; 7(2):720-30.
    View in: PubMed
    Score: 0.004
  215. Tardive dystonia in patients with Tourette's syndrome. Mov Disord. 1988; 3(3):274-80.
    View in: PubMed
    Score: 0.004
  216. Orofacial and other self-mutilations. Adv Neurol. 1988; 49:365-81.
    View in: PubMed
    Score: 0.004
  217. Blepharospasm and cranial-cervical dystonia (Meige's syndrome): familial occurrence. Adv Neurol. 1988; 49:117-23.
    View in: PubMed
    Score: 0.004
  218. Coexistent tardive dyskinesia and parkinsonism. Clin Neuropharmacol. 1987 Dec; 10(6):511-21.
    View in: PubMed
    Score: 0.004
  219. Motor, behavioral and pharmacologic findings in Tourette's syndrome. Can J Neurol Sci. 1987 Aug; 14(3 Suppl):541-6.
    View in: PubMed
    Score: 0.004
  220. A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's disease. Parkinsonism Relat Disord. 2008; 14(1):77-80.
    View in: PubMed
    Score: 0.004
  221. Blepharospasm and autoimmune diseases. Mov Disord. 1987; 2(3):159-63.
    View in: PubMed
    Score: 0.004
  222. Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Mov Disord. 2007 Jan; 22(1):55-61.
    View in: PubMed
    Score: 0.004
  223. Genomewide scans in North American families reveal genetic linkage of essential tremor to a region on chromosome 6p23. Brain. 2006 Sep; 129(Pt 9):2318-31.
    View in: PubMed
    Score: 0.004
  224. Topiramate in essential tremor: a double-blind, placebo-controlled trial. Neurology. 2006 Mar 14; 66(5):672-7.
    View in: PubMed
    Score: 0.004
  225. The phenomenology of tics. Mov Disord. 1986; 1(1):17-26.
    View in: PubMed
    Score: 0.004
  226. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005 Jul; 20(7):783-91.
    View in: PubMed
    Score: 0.003
  227. Examination of the SGCE gene in Tourette syndrome patients with obsessive-compulsive disorder. Mov Disord. 2004 Oct; 19(10):1237-8.
    View in: PubMed
    Score: 0.003
  228. Apolipoprotein E controls the risk and age at onset of Parkinson disease. Neurology. 2004 Jun 08; 62(11):2005-9.
    View in: PubMed
    Score: 0.003
  229. Phenotypic features of Huntington's disease-like 2. Mov Disord. 2003 Dec; 18(12):1527-30.
    View in: PubMed
    Score: 0.003
  230. Association study of Parkin gene polymorphisms with idiopathic Parkinson disease. Arch Neurol. 2003 Jul; 60(7):975-80.
    View in: PubMed
    Score: 0.003
  231. A heteroplasmic mitochondrial complex I gene mutation in adult-onset dystonia. Neurogenetics. 2003 Aug; 4(4):199-205.
    View in: PubMed
    Score: 0.003
  232. Substantia nigra lesions in viral encephalitis. Mov Disord. 2003 Feb; 18(2):213-6.
    View in: PubMed
    Score: 0.003
  233. Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet. 2003 Jan; 33(1):85-9.
    View in: PubMed
    Score: 0.003
  234. Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson's disease. Neurology. 2002 Mar 26; 58(6):881-4.
    View in: PubMed
    Score: 0.003
  235. Intrafamilial phenotypic variability of the DYT1 dystonia: from asymptomatic TOR1A gene carrier status to dystonic storm. Mov Disord. 2002 Mar; 17(2):339-45.
    View in: PubMed
    Score: 0.003
  236. Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA. 2001 Nov 14; 286(18):2239-44.
    View in: PubMed
    Score: 0.003
  237. Identification of a high frequency of mutation at exon 8 of the ATP7B gene in a Chinese population with Wilson disease by fluorescent PCR. Arch Neurol. 2001 Nov; 58(11):1879-82.
    View in: PubMed
    Score: 0.003
  238. Alcohol dehydrogenase polymorphism and Parkinson's disease. Neurosci Lett. 2001 Jun 01; 305(1):70-2.
    View in: PubMed
    Score: 0.003
  239. Comparison of thalamotomy and pallidotomy for the treatment of dystonia. Neurosurgery. 2001 Apr; 48(4):818-24; discussion 824-6.
    View in: PubMed
    Score: 0.003
  240. Long-term efficacy of posteroventral pallidotomy in the treatment of Parkinson's disease. Neurology. 2000 Oct 24; 55(8):1218-22.
    View in: PubMed
    Score: 0.002
  241. Polymorphism of NACP-Rep1 in Parkinson's disease: an etiologic link with essential tremor? Neurology. 2000 Mar 14; 54(5):1195-8.
    View in: PubMed
    Score: 0.002
  242. Bruxism in Huntington's disease. Mov Disord. 2000 Jan; 15(1):171-3.
    View in: PubMed
    Score: 0.002
  243. The alpha-synuclein gene is not a major risk factor in familial Parkinson disease. Neurogenetics. 1999 Sep; 2(3):191-2.
    View in: PubMed
    Score: 0.002
  244. Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J Neurol Neurosurg Psychiatry. 1999 May; 66(5):612-6.
    View in: PubMed
    Score: 0.002
  245. The G209A mutation in the alpha-synuclein gene is not detected in familial cases of Parkinson disease in non-Greek and/or Italian populations. Arch Neurol. 1998 Dec; 55(12):1521-3.
    View in: PubMed
    Score: 0.002
  246. Posteroventral medial pallidotomy for treatment of Parkinson's disease: preoperative magnetic resonance imaging features and clinical outcome. J Neurosurg. 1998 Aug; 89(2):194-9.
    View in: PubMed
    Score: 0.002
  247. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol. 1998 Jul; 55(7):969-78.
    View in: PubMed
    Score: 0.002
  248. Pallidotomy for generalized dystonia. Mov Disord. 1998 Jul; 13(4):693-8.
    View in: PubMed
    Score: 0.002
  249. Assessment of motor function after stereotactic pallidotomy. Neurology. 1998 Jan; 50(1):266-70.
    View in: PubMed
    Score: 0.002
  250. Symptomatic and functional outcome of surgical treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1997 Nov; 63(5):642-8.
    View in: PubMed
    Score: 0.002
  251. Microelectrode-guided posteroventral pallidotomy for treatment of Parkinson's disease: postoperative magnetic resonance imaging analysis. J Neurosurg. 1997 Sep; 87(3):358-67.
    View in: PubMed
    Score: 0.002
  252. Posteroventral medial pallidotomy in levodopa-unresponsive parkinsonism. Arch Neurol. 1997 Aug; 54(8):1026-9.
    View in: PubMed
    Score: 0.002
  253. Ecstasy intoxication: an overlap between serotonin syndrome and neuroleptic malignant syndrome. Clin Neuropharmacol. 1996 Apr; 19(2):157-64.
    View in: PubMed
    Score: 0.002
  254. Neurologic presentation of Wilson disease without Kayser-Fleischer rings. Neurology. 1996 Apr; 46(4):1040-3.
    View in: PubMed
    Score: 0.002
  255. Outcome after stereotactic thalamotomy for dystonia and hemiballismus. Neurosurgery. 1995 Mar; 36(3):501-7; discussion 507-8.
    View in: PubMed
    Score: 0.002
  256. A comparison of postspace-flight orthostatic intolerance to vasovagal syncope and autonomic failure and the potential use of the alpha agonist midodrine for these conditions. J Clin Pharmacol. 1994 May; 34(5):466-71.
    View in: PubMed
    Score: 0.002
  257. Extrapyramidal involvement in Rett's syndrome. Neurology. 1990 Feb; 40(2):293-5.
    View in: PubMed
    Score: 0.001
  258. Rett syndrome and associated movement disorders. Mov Disord. 1990; 5(3):195-202.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.